BioWorld

March 16, 2005

Avastin's Survival Data In NSCLC Sends Genentech Soaring, Again

Genentech Inc.'s stock climbed 25 percent in late-day trading Monday after news that a Phase III trial of Avastin met its primary endpoint of survival in non-small-cell lung cancer patients. (BioWorld Today) Read More

ViaCell Gets Patent, Signs Deal With Genzyme; Stock Moves Up

In Very Early Going, Killing Cancer Cells Indiscriminately

CVBT Completes IPO, Gets $17M For Vascular Product

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...